Rule #1 – The Chairman Doesn’t Wait

Clock’s ticking.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

August 12, 2024 UNSUBSCRIBE

The Reason I Called in ‘The Chairman’… JAMES ALTUCHER Dear Reader, Hey, it’s James Altucher. I’m excited to see you at our upcoming, “A-List” event at 7pm E.T. on August 15th. It can’t come soon enough – because “the Chairman” doesn’t wait. Not when an opportunity is this big. That’s how he predicted Nvidia’s rise… When the company traded at only 50-cents per share, split adjusted. And on the flipside, he’s a bona fide tech prodigy – a self-taught engineer.  For instance… At the age of 15, The Chairman blew the science community’s collective minds when he recreated a Nobel Prize winning nuclear detector in his parents’ garage. Years later, he harnessed these talents to become one of the nation’s most elite programmers. Building network architecture for a $30 billion private investment firm. Which is how The Chairman’s deep knowledge of technology permanently intertwined with finance. And it’s also what makes him such an anomaly… In The World of Tech and Finance, The Chairman is a “Unicorn”. I say that because people with his talent… skillset… and expertise do not typically exist. Just think about it… How many people on this planet can: ✓ Write and interpret complex code and computer algorithms… ✓ Reverse engineer intricate nuclear devices in their free time…   And still have the time and energy to… ✓ Analyze thousands of the world’s most groundbreaking tech stocks, and successfully pinpoint exactly which ones have 500% potential. That’s why the guy is in a league of his own. And when The Chairman has a bold prediction about tech… finance… or the emergence of a new, disruptive technologies… …I have no choice but to listen. Whether that’s nuclear technology… software algorithms… circuits… semiconductors… even groundbreaking forms of energy… The Chairman knows how it works. If it’s feasible. And most importantly, he knows EXACTLY what the financial implications could be. And you may be wondering… Why Do I Want YOU to Meet Him? It’s simple. While he is a well-known name, across the board, in the world of tech investing…. The Chairman is the #1 guy in ONE specific avenue of tech… Biotech. And there’s a few reasons why this is critical to what’s on the docket for our meeting on August 15th… First of all… The Biotech Markets Have Been Quietly BOOMING Throughout 2024. We’ve seen gains like 202% on Arcutis Biotherapeutics – in just 8 months. Within the same time frame another biotech firm, Summit Therapeutics, has surged by 362%. And in just 10 months, Avidity Biosciences has skyrocketed by more 450%. These are just a few of the best small-cap biotech stocks that have posted triple-digit returns in 2024. But according to my sources this is only the beginning. You see… In Just a Few Days, a MASSIVE AI Project is Going to Radically Transform the Biotech Industry. Yet most of this has been ignored by the news due to the chaos surrounding the election. This is primary reason that I’ve called in The Chairman.  He’s one of the most well-connected experts in the biotech business.  He knows all the key players… scientists… doctors… researchers in this space. AND… He’s on a first name basis with several of the CEO’s and C-Suite executives that run the industry.  Heck, he even flies private with them from time to time. That’s why I believe: Right now, The Chairman has a level of access – and insights – that are truly invaluable. And on August 15th He’s Agreed to Help Us Capitalize on This Urgent Situation – Before AI Permanently Disrupts the $1.6 Trillion Biotech Industry. After speaking with him about this, I believe it really could be a once in a lifetime wealth opportunity. Just think about it… We already KNOW the AI markets are one of the hottest markets in history. And on the other hand, small biotech stocks have performed outstandingly too – with gains as high as 900% in the last year. So… What do you think is going to happen when these two unstoppable industries permanently intertwine on August 23rd? Well, according to The Chairman – who knows exactly how Wall Street reacts to biotech situations like this… He believes this AI Biotech catalyst on August 23rd could ignite a historic flood of institutional capital. I’m talking about trillions of dollars, pouring into a handful of firms in just a single day. And here’s the kicker… The companies that are leading this charge into AI Healthcare are TINY. Some of these companies are valued at less than $50 million. But in just a few days – when this catalyst takes place – these companies could begin to RAPIDLY multiply. The Chairman is Predicting Several Returns of 500% - or More – Within the Next 18 Months. Truthfully, I think that’s a conservative estimate. But with numbers like that, this situation could be lifechanging. That’s why I’m excited for you to hear all of this, from him, on August 15th. During the event, The Chairman is going to cover everything… You’re going to learn: ✓ EXACTLY what’s happening behind the scenes with this historic AI Biotech Project – that could SHOCK the markets when it unveils on August 23rd… ✓ DETAILS about the most promising stocks in this new frontier of AI (3 special stocks The Chairman has handpicked for the biggest returns). You’ll learn about these stocks at the event on August 15th – so you’ll have more than 7 days to make a move on them. ✓ SPECIFIC INSTRUCTIONS about how to find the best AI Biotech stocks for yourself. It’s special strategy The Chairman uses to pinpoint optimal dates and prices to invest. So, there’s A LOT to be excited about here. I know I’m excited to just introduce you to this legendary investor. And on August 15th, I have no doubt you are going to benefit massively from this opportunity. So, I’ll leave it at that for now. But… Keep your eye out for an email from me tomorrow afternoon. I want to relay a little more information from The Chairman. Including a few VERY important details about this special AI Biotech Project that’s going to be unveiled on August 23rd. I think it will help you understand why the financial implications could be unlike anything we’ve seen in history. I’ll have the full details for you tomorrow. In the meantime… Click here to go to our event page to get caught up. See you then, James Altucher

© 2024 Paradigm Press, LLC. 1001 Cathedral Street, Baltimore, MD 21201. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your Altucher's A-List e-mail subscription and associated external offers sent from Altucher's A-List, feel free to click here. Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@paradigmpressgroup.com. This address is for feedback only. For questions about your account or to speak with customer service, contact us here or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Altucher's A-List is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our Privacy Statement. If you are having trouble receiving your Altucher's A-List subscription, you can ensure its arrival in your mailbox by whitelisting Altucher's A-List.